Rritual Announces Dr. Mike Hart as President

“My belief is that mental fitness is a daily ritual, Rritual’s product portfolio and approach completely supports my current research and values as a plant-based practitioner,” said Dr. Mike Hart.

VANCOUVER, British Columbia (PRWEB)
June 23, 2020

Rritual, the premium brand in the emerging functional mushroom market, announced today that Dr. Mike Hart has been named as the President of North America’s leading mushroom adaptogens company.

Dr. Hart has more than 6 years of experience in plant based therapy, including owning and operating his own family medicine clinic in London, Ontario, Canada where he regularly integrates plant-based wellness techniques, seeing optimal success with his patients in supporting them to treat common symptoms such as pain, inflammation, insomnia, depression and much more. His mission is to help his patients integrate plant-based therapies to lead the healthiest lifestyle possible.

Rritual, the rapidly growing North American leader in the emerging functional mushroom market is transforming the functional food industry with their Reishi, Chaga, Cordyceps, and Lion’s Mane mushroom focused super food product portfolio which currently includes elixirs, mixes and shots combined with synergistic adaptogenic herbs. Their data-backed, unique formulations for their premium, plant-based elixirs include key ingredients to help support cognitive function, stress relief, and boost immunity.

“Dr. Mike Hart is the perfect leader for Rritual,” said David Kerbel, Chief Executive Officer. “Dr. Hart’s extensive plant-based medicine background, business development skills, passion for health and wellness, and extensive trusted platform significantly strengthens our rapid expansion, brand presence and scalability in the emerging functional mushroom market,” Kerbel added.

“I am very excited to be joining the Rritual team,” said Dr. Mike Hart. “I believe Rritual has a great business model and, product portfolio in addition to a talented, and passionate management team that uniquely positions it for success in the emerging plant-based industry. Their mission to help people adapt to modern life and prove that mushrooms are one of the world’s greatest superfoods, is a perfect fit with my own wellness practices as a Physician, and personally as an individual who is passionate about mental and physical health.”

“My belief is that mental fitness is a daily ritual, and Rritual’s product portfolio and approach completely supports my current research and values as a seasoned, plant-based practitioner, having the tools and products available to individuals to help support their mental and physical fitness is of the utmost importance,” Hart added.

Currently one of the world’s foremost experts in plant-based medicine, In September of 2002, Dr. Hart began studying nutritional biochemistry at Memorial University and completed his degree in 2006. After completing his undergraduate degree he obtained his medical degree at Saba School of Medicine in the Netherlands Antilles from 2006-2010. In 2014, Dr. Hart became the first physician in London, Ontario, Canada to open a Cannabis Clinic. His passion for helping patients with wellness tools runs deep with having supported thousands of patients to live symptom-free and lead healthier lifestyles since he began practicing medicine. He is also the co-author of the Amazon Best Seller “Friendly Fire”: Why Vets Are Lighting Up and Ditching Pills to Treat PTSD.

About Rritual

Launched in 2020, Rritual is guided by a single purpose: to help each and everyone meet the demands of modern life with style and ease through mushroom adaptogens. Rritual makes premium plant-based elixir products in small batches featuring mindfully-selected medicinal mushrooms and adaptogenic herbs. To help support and achieve an optimal need-state, Rritual offers a range of products to fit every lifestyle. Rritual produces simple mushroom adaptogen products with limited, yet very purposeful and organic ingredients. Most of all, Rritual wants to help people adapt to the strain of modern life and prove that mushrooms truly are the world’s greatest superfoods. You can find out more about Rritual by visiting https://wearerritual.com/ or find them on Twitter, Instagram, LinkedIn, and Facebook.

About Dr. Mike Hart

Dr. Michael Hart, M.D, is one the world’s most foremost experts on plant based medicine. In 2014, Dr. Hart became the first physician in London, Ontario, Canada to open a Cannabis Clinic. In 2016 he founded Readytogo Medical Clinic, where he currently acts as the lead physician and medical director. He is also the co-author of the Amazon Best Seller “Friendly Fire”: Why Vets Are Lighting Up and Ditching Pills to Treat PTSD and the Candian Medical Ambassador for Athletes for CARE. His outspoken stance has landed him on a variety of media outlets, including an appearance on the Joe Rogan Experience Podcast which received over 3.2M views to date. You can find out more about Dr. Hart by visiting his website: https://mikehartmd.com/ or find him on Twitter, Instagram, LinkedIn, Facebook, YouTube.

For more Information, or press inquiries contact:

Jess Moran

Principal & Founder, JESSCO

jess@jessmco.com

519-494-5379

Share article on social media or email:

Anesthesia Progress volume 67 issue 1

Of particular note was the splatter found behind the face shield and underneath the chin of the anesthesiologist, illustrating just how impactful a cough can be at releasing the SARS-CoV-2 virus.

LAWRENCE, Kan. (PRWEB)
June 23, 2020

Anesthesia Progress—Receiving dental care during the COVID-19 pandemic has been extremely challenging for patients and providers alike. The virus, which is primarily found in oral, nasal, and pharyngeal mucosa and in pulmonary secretions, is an air-borne contaminant and spreads through respiratory droplets, contact contamination, or by aerosols produced during aerosol-generating procedures (AGPs). Given the transmission type, four of the top five professions at the highest risk for the contracting the virus are within the dental field. It is of the upmost importance that appropriate protective measures are put into place before routine dental care can resume as normal.

Researchers from the University of Toronto, University of Vancouver, and private practice in British Columbia published a study in the current issue of Anesthesia Progress that examined the extent of splatter produced during an AGP or coughing while receiving dental care.

To simulate a dental procedure and examine the extent of splatter, the researchers used a dental mannequin fitted with a set of model teeth coated in Glo Germ™, which appears blue under an ultraviolet (UV) light. While wearing short-sleeved scrubs, goggles, a surgical mask, and gloves, a dentist and dental hygienist performed three different dental procedures on the mannequin using a high-speed handpiece, an ultrasonic scaler, and an air-water syringe; all three were done with continuous use of high-volume suction. To simulate a cough during a procedure, a ventilator was equipped with and programmed to release Glo Germ™ during the procedure. During this simulation a dentist anesthesiologist was introduced wearing the same personal protective equipment (PPE) as the dentist and hygienist, with the addition of a face shield. After each procedure or cough, the participants were taken to a dark room where UV light was used to examine splatter patterns and photographs were taken and analyzed to document the extent of the splatter.

The researchers found that after each AGP was performed, both the dentist and hygienist had splatter on their face, body, arms, and legs. The simulated cough showed an increased amount of splatter produced, and, in addition to their face, body, arms, and legs, the dentist and hygienist had splatter on the crown of their head, back, and shoes. The anesthesiologist had a significant amount of splatter on every surface of the body, except for the back and shoes. Of particular note was the splatter found behind the face shield and underneath the chin of the anesthesiologist, illustrating just how impactful a cough can be at releasing the SARS-CoV-2 virus.

The researchers conclude that in addition to eye protection, masks, and gloves, dental professionals should also wear face shields, bouffant/surgical caps, and shoe coverings to fully protect themselves from the virus. This full set of PPE should also be changed between patients to avoid cross-contamination of the patients or staff during procedures that generate AGPs.

Full text of the article, “Aerosol Generating Procedures and Simulated Cough in Dental Anesthesia,” Anesthesia Progress, is now available here.

###

About Anesthesia Progress

Anesthesia Progress is the official publication of the American Dental Society of Anesthesiology (ADSA). The quarterly journal is dedicated to providing a better understanding of the advances being made in the science of pain and anxiety control in dentistry. The journal invites submissions of review articles, reports on clinical techniques, case reports, and conference summaries. To learn more about the ADSA, visit: http://www.adsahome.org/.

Share article on social media or email:

PREDICT96 is an organ-on-a-chip device seamlessly configured into an industry-standard multiwell cell culture plate.

As the global pandemic of COVID-19 continues to grow, our system has the potential to quickly evaluate antiviral and repurposed drugs to help combat this devastating disease. – Ashley Gard, Senior Member of the Technical Staff, Draper

CAMBRIDGE, Mass. (PRWEB)
June 23, 2020

Draper today announced the release of a new scientific article that describes how the company’s technology can be used to test an in vitro human lung model to investigate responses following infection with COVID-19 and influenza. The study was part of a collaboration between Draper and the University of Massachusetts Medical School. The manuscript, titled “High-Throughput Human Primary Cell-Based Airway Model for Evaluating Influenza, Coronavirus, or other Respiratory Viruses in vitro,” was posted in bioRxiv.

Several preclinical research tools are available to model respiratory infections, but due to the complexity of the human lung and requirements to accurately model host-virus interactions, these models provide a poor correlation as a basis for guiding clinical strategy. As many scientists are asking for models with stronger in vitro-in vivo correlation, the scientific community begins to turn more towards using organ-on-a-chip systems as a cost-effective and more accurate way to develop therapies.

Draper, in collaboration with UMass Medical School, describe an in vitro, microfluidic system containing functioning patient-derived human airway cells, which mature into human lung tissue that researchers monitored using integrated sensing and studied following controlled exposure to infectious respiratory pathogens. The PREDICT96 platform allows scientists to accurately mimic the structure and function of human lung tissues derived from donors with different patient profiles and sustain human tissue organ models for several weeks of automated testing.

“One of the greatest barriers to the development of effective therapeutic agents to treat influenza, coronaviruses and many other infections of the respiratory tract is the absence of a robust preclinical model. As the global pandemic of COVID-19 continues to grow, our system has the potential to quickly evaluate antiviral and repurposed drugs to help combat this devastating disease,” said Ashley Gard, Senior Member of the Technical Staff at Draper.

Current preclinical models typically rely on high-throughput, low-fidelity in vitro screening with cell lines or low-throughput animal models that often provide a poor correlation to human clinical responses. Emerging organ-on-chip models have the potential to overcome these limitations, but are often designed for research environments and are often incompatible with workflows and standard instrumentation in pharmaceutical laboratories.

In contrast, PREDICT96 is an organ-on-a-chip device seamlessly configured into an industry-standard multiwell cell culture plate, comprising 96 individual co-culture devices and a perfusion system driven by 192 microfluidic pumps integrated into the plate lid. Pairs of microchannels within each device, each less than a millimeter in diameter, are separated by a biomimetic semi-permeable membrane lined with human cells and arranged in complex configurations to support growth of human tissue. The device enables researchers to grow 96 human lung tissues at once and conduct 96 simultaneous experiments in order to evaluate different respiratory viruses, viral doses, viral strains and tissue from unique donors.

In the study, researchers evaluated the lung model’s responses to influenza A virus (IAV) and coronavirus (HCoV-NL63) and observed the behavior of airway cells in response to different therapeutic drug regimens. Results indicate that PREDICT96 can be used to model the human lung and its response to IAV and coronavirus infections, and could potentially be used to screen the efficacy of candidate therapeutics in a clinically relevant manner.     

“The most striking features of our organ-on-a-chip is that it captures different reactions to respiratory viral infection by influenza and coronavirus, as well as detected expressions of ACE2 and TMPRSS2,” said Joe Charest, Ph.D., Head of Strategy and Business Development, Pharmaceutical R&D Technologies at Draper. The ACE2 receptor and TMPRSS2 protein play key roles in COVID-19 infections, and their presence is critical to the ability to model the infection process. Draper has expanded use of PREDICT96 beyond testing drug interactions with liver, kidney, vascular, gum and gastrointestinal tissue models to the new application for COVID-19, Charest added.

Funding was provided by Draper for the coronavirus research and by Defense Advanced Research Projects Agency (DARPA) for the influenza A virus research under its PREPARE program. Last year Draper and UMass Medical School, while working on the PREPARE program, announced the first instance of a dynamic air-liquid interface model using patient-derived cells for influenza testing.

Dr. Robert W. Finberg, an investigator on the team and chair of Medicine at UMass Medical School and UMass Memorial Medical Center, said COVID-19 is a natural extension of the PREPARE research. “Several of us working primarily on influenza are very excited about working on this new virus and finding different ways to prevent the disease it causes,” he said.

To read the full manuscript, please visit https://www.biorxiv.org/content/10.1101/2020.05.23.112797v1

Share article on social media or email:

A one-on-one ABA therapy room at Lighthouse Autism Center in Mishawaka.

This partnership has created a wonderful opportunity for our organizations to advance our shared mission of providing the best possible services to the children and families we serve.

MISHAWAKA, Ind. (PRWEB)
June 23, 2020

Lighthouse Autism Centers, LLC (“Lighthouse” or the “Company”), a leading provider of center-based, Applied Behavioral Analysis (“ABA”) therapy, today announced the acquisition of Autism Therapy Services, LLC (“ATS”), a rapidly-growing, center-based ABA provider in the greater-Indianapolis market. This acquisition will make Lighthouse Autism Center one of the largest ABA providers in the state of Indiana. This acquisition will allow Lighthouse to expand its service area, and accelerate the Company’s strategy to bring the highest-quality ABA service to communities across Indiana and Michigan.

“The ATS team has strong, data-driven, clinical processes in place and a passion for helping children and families, two critical areas that align perfectly with the Lighthouse mission and values,” said Gregg Maggioli, Lighthouse’s co-founder and CEO. “We couldn’t be more excited or proud to welcome ATS to the Lighthouse family.”

Michael Mitchell, CEO of Autism Therapy Services commented that, “Lighthouse has the resources, talent and experience to help our team further its mission. This partnership has created a wonderful opportunity for us to work with a larger, well-capitalized organization that will enable us to further invest in our staff and technology infrastructure to deliver the best possible services for the children and families we serve.”

About Lighthouse Autism Center

Headquartered in Mishawaka, Indiana, Lighthouse was founded in 2012 by Gregg and Sandy Maggioli, the parents of a child with autism. Over the past 8 years, Lighthouse has grown into a leading center-based provider of ABA therapy for children on the autism spectrum, with a network of centers across northern Indiana and southwestern Michigan. The Company’s state-of-the-art centers focus on providing intensive one-on-one ABA therapy to children ages 2-18. For more information about Lighthouse, visit the company’s website at: http://www.lighthouseautismcenter.com.

About Autism Therapy Services

Headquarters in Indianapolis, Indiana, Autism Therapy Services is a center-based ABA provider that provides ABA services through a network of five centers across the greater Indianapolis area. In addition to ABA therapy, ATS also provides speech therapy, occupational therapy, as well as diagnostic services for families.

Media Contact:

Maggie Gendel

Director of Marketing and Support Services

(574) 386-4321

Share article on social media or email:

CHICAGO (PRWEB)
June 23, 2020

Oak Street Health, a network of primary care centers that delivers value-based care to adults on Medicare, today announced further plans for nationwide expansion in 2020 with the company’s first centers in New York and Mississippi anticipated to open later this year. The company plans to open two locations in Brooklyn, N.Y., and a new center in Jackson, Miss.

“The planned opening of our first centers in New York and Mississippi represents a continued commitment to providing access to innovative, high-quality, value-based primary care to older adults where it is most needed across the country,” said Tamara Jurgenson, Chief Growth Officer of Oak Street Health. ​“We are excited to introduce our model of care to seniors in these new communities.”

Oak Street Health is continuing to move forward with growth plans while also focusing efforts on caring for the company’s more than 85,000 patients across more than 50 centers in eight states during the COVID-19 pandemic. Prior to the pandemic, Oak Street Health opened its first center in Tennessee and also announced plans to enter the state of Texas with centers anticipated to open in the greater Dallas-Fort Worth area by early fall.

“We have been able to meet the unique challenges presented by the pandemic, and our ability to adapt and provide care for our patients at this critical time is a testament to Oak Street Health’s innovative value-based healthcare model,” said Mike Pykosz, CEO of Oak Street Health. ​“Our patients always come first and with our upcoming entry into New York and Mississippi, we are furthering our company’s mission of rebuilding healthcare as it should be.”

Oak Street Health patients can expect an unmatched healthcare experience that includes quality time with their provider in-person or via telehealth visit; a 24/7 patient support line; individualized, preventive care plans; and access to transportation to and from the center for eligible patients. Additional services, such as behavioral health care and social health support, and Medicare education classes, are also offered to help older adults meet their unique needs in one convenient location.

Since its founding in 2012, Oak Street Health has seen a 51 percent reduction in patient hospital admissions compared to Medicare benchmarks. Oak Street Health will accept multiple health plans at all locations, including traditional Medicare.

To learn more about Oak Street Health’s value-based primary care model, click here.

About Oak Street Health

Founded in 2012, Oak Street Health is a fast-growing network of value-based, primary care centers for adults on Medicare. With a mission of rebuilding healthcare as it should be, the company operates an innovative healthcare model focused on quality of care over volume of services, and assumes the full financial risk of its patients.

Oak Street Health currently operates more than 50 centers across Illinois, Michigan, Indiana, Pennsylvania, Ohio, Rhode Island, North Carolina and Tennessee, with plans to continue its geographic expansion, including into Texas, New York and Mississippi in 2020. To learn more about Oak Street Health’s proven approach to care, visit oakstreethealth.com

Share article on social media or email:

Invictus

In a busy NICU, anything we can do to help with the early identification of status changes in the condition of a sick child is beneficial, both for the infant and for the stretched nursing staff.

SAN ANTONIO (PRWEB)
June 23, 2020

Invictus Medical, the San Antonio, Texas-based medical device company dedicated to providing newborns with healthy developmental milestones, has acquired the worldwide license to an exciting new technology that analyzes the audible sounds generated by neonates, providing guidance to clinical staff. The technology holds the promise of providing clinicians with clues about the health status of premature infants, whether isolated in incubators or in a crowded open unit, helping to prioritize nursing activities.

“In a busy NICU, anything we can do to help with the early identification of status changes in the condition of a sick child is beneficial, both for the infant and for the stretched nursing staff,” said George Hutchinson, Invictus Medical’s Chief Executive Officer. “This should make a great extension to Invictus’ Neoasis™ incubator-based noise attenuation system.”

The cry and vocalization analysis technology was originally developed in the Digital Signal Processing Laboratory of Northern Illinois University, a nationally recognized center for acoustic applications founded by Professor Emeritus Sen Kuo and currently led by Professor Lichuan Liu. Invictus Medical and Northern Illinois University have collaborated since 2015 in the space of acoustic signal analysis.

About Invictus Medical

Invictus Medical is a San Antonio, Texas-based medical device company that aims to ensure that children are able to attain their developmental milestones. As evidenced by their award-winning innovations, Invictus Medical has been at the forefront of pediatric care since its founding in 2012. Invictus Medical is a privately held company. For more information about Invictus Medical, please see http://www.invictusmed.com.

Share article on social media or email:

FAST FOLD portable solar power system being deployed

Deployed within minutes, the portable FAST FOLD solar power system can provide 100% self-sustaining power for medical equipment, without reliance on the grid or diesel supplies

MILTON KEYNES, England (PRWEB)
June 23, 2020

First Aid Africa, a Scottish charity with operations in Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable renewable energy equipment, have announced the success of a rapid response project to support testing operations in the fight against the COVID-19 pandemic in Zambia.

One of Renovagen’s FAST FOLD portable solar power systems was deployed by First Aid Africa to Mbereshi Mission Hospital following an urgent request. The hospital was struggling with delivery of tests because power was available for only 6 hours a day and it was extremely unreliable. Due to logistical and procurement restrictions, fuel for generators was not available at the site. This limited the number of tests which could be completed, and caused valuable reagents to be wasted as tests were being interrupted by power outages. With reagents being in such short supply, this was a critical issue.

First Aid Africa responded by sending one of their FAST FOLD portable solar power systems on a 14 hour drive across the country to the hospital site, where it was set up within minutes to provide a stable source of clean power for the testing equipment at the hospital. The small size and weight of the system meant that it could be transported by pickup truck and manually deployed without the need for special equipment. The unique design, with single-button operation, meant that no specialist skills were needed to set up and run the FAST FOLD system. First Aid Africa plan to leave the system in place to support the COVID-19 response, until funding can be raised for a permanent off-grid solar power installation at the site. At that time, the FAST FOLD system can be moved to another location with a critical need for power.

John Hingley, Managing Director of Renovagen Ltd said, “This case study demonstrates the benefits of portable solar power equipment as a critical interim solution in healthcare settings. The FAST FOLD system has proven itself to be an extremely flexible tool for fast response in remote locations where the use of heavy equipment to deploy larger systems may not be practical and specialist electrical skills may not be available. Whether the driving factor for urgency is a global pandemic, a natural disaster or population displacement, there will continue to be many scenarios where self-sustaining power is required at sites that are difficult to access. Often, the provision of that power without reliance on fuel for generators can be life-saving. We are proud to have partnered with First Aid Africa to provide this capability that enhances their great work in Africa.”

“The FAST FOLD system can provide 100% self-sustaining power for medical equipment, without reliance on the grid or diesel supplies”, states Sam Abrahams, CEO of First Aid Africa. “It has proved to be a flexible asset for supporting a range of our operations – from First Aid training in remote villages to urgent response to critical healthcare issues such as the COVID-19 pandemic. Having a kW-scale portable solar capability – which can be packed up within a few minutes by hand, transported by pickup truck and redeployed just as quickly – is hugely valuable. This has had a direct impact on the number of COVID-19 tests being completed, so it is positively contributing to the national response, helping to contain the virus and ultimately to save lives.”

Josephat Moyo, Medical Laboratory Technologist at Mbereshi Mission Hospital said “I would like to acknowledge and thank First Aid Africa for providing the FAST FOLD portable solar generator to our institution. We are using it to power Pentra C200 and Gene Xpert machines used for COVID-19 testing and are extending it to power blood count/CD4 count machines as well. This has helped the laboratory to have a stable energy supply – which is especially valuable because before we had the FAST FOLD system we would usually experience power supply interruptions during the course of our work. The result has been improved turn-around times for test results and a reduction in wastage of reagents.”

We welcome press enquiries and investment/funding enquiries to assist in scaling up and increasing the impact of our projects.

Contact:

• 
  Renovagen Ltd – EMEA – Colin Miller – colin.miller@renovagen.com Tel: +44 1908 766349
• Renovagen, Inc. – Americas – John Hingley – john.hingley@renovagen.com Tel: +1 239 238 5490
• First Aid Africa – Sam Abrahams – samabrahams@firstaidafrica.com Tel: +260 762582976

Share article on social media or email:

…Azalea Health has done a great job of enabling our practice through their telehealth technology. Having a fully HIPAA-compliant, integrated telehealth solution that is easy to use and deploy has empowered my staff and patient community…

ATLANTA (PRWEB)
June 23, 2020

Azalea Health, a leading provider of fully cloud-based patient management and billing solutions serving more than 15 million patients, today announced the results of its free telehealth initiative, offered to community-based healthcare providers using Azalea EHR for one year during the COVID-19 pandemic.

Not only did providers take advantage of the offer, sessions increased 68-fold from February to April, representing a 6,500% jump since the initiative was launched in early March, and $2.3M in reimbursements. The trend is not showing any signs of slowdown — telehealth sessions remained 4,000% higher in May compared to February. The fast and widespread adoption of Azalea’s telehealth offering points to the promising potential of telehealth as the new staple of patient care — expanding the reach of care teams, enabling higher utilization, and unlocking a strong path to revenue recovery.

Providers have been using Azalea’s telehealth app to support a wide range of clinical activities, including managing chronic illness, performing wellness checks, providing medication management for OB/GYN patients, ensuring continuity of behavioral health services for high-risk youth, and extending the reach of their care teams.

“We could not be more proud to provide a critical telehealth service to our growing network of providers, just in time to help them continue to serve their patient communities through this unprecedented crisis,” said Baha Zeidan, Azalea Health CEO. “Our ability to pivot quickly is part of our DNA; this agility is inherent to our cloud-based infrastructure. As telehealth becomes the new standard, we’re excited to offer it to providers and patients as part of a holistic care management solution, tightly integrated with our ‘one patient, one record’ approach to EMR and flexible billing system. Providers are using this to not only bridge the gap to revenue recovery, but also to build towards a vibrant practice of the future.”

A recent report from McKinsey found that 76% of patients were interested in using telehealth going forward, up from 11% before COVID-19, while 56% of providers view telehealth more favorably than they did before the pandemic. The shift to telehealth has been especially vital for rural health clinics (RHCs), 51% of which did not have any telehealth services in 2018. Health centers are now seeing just 63% of their patient volume before the pandemic, forcing over 1,700 of them to temporarily close. Telehealth is now enabling care continuity for the vulnerable populations that rely on these RHCs for their healthcare.

“This pandemic opened the door for telehealth, and now it’s unlikely that door will ever close again,” noted rural healthcare consultant Mark Lynn. “Now that the regulatory hurdles have been cleared and evidence of success emerges, providers are starting to see telehealth as a long-term solution. Patients are expecting touch-free and remote care options, and with patient volumes still below pre-COVID levels, telehealth will be critical to stabilizing revenue. It can also help patients reach specialists they would never have had access to before.”

Azalea’s telehealth offering is an agile, intuitive end-to-end solution that streamlines the remote patient care workflow and integrates it with the patient record for a seamless extension of care. It comes fully integrated with electronic prescribing capabilities and a patient portal that delivers access to patient records, appointment scheduling, messaging and payment options. With the familiar look, feel and functionality of an app, providers and patients can spend less time learning how the technology works and more time on the clinical visit. And although patient privacy rules for telehealth have relaxed during the crisis, Azalea’s telehealth offering is fully HIPAA-compliant.

“We were looking at telehealth as a way to augment the services that we offer to our patients long before the current COVID-19 crisis,” said Omar L. Caban, MD, MBA, president at Phycinity PLLC, a pediatric provider delivering services in the greater Raleigh, North Carolina area. “What the pandemic did was reduce the regulatory and payer-related barriers to payment standing in the way of revenue and a truly profitable model for remote care. Azalea Health has done a great job of enabling our practice through their telehealth technology. Having a fully HIPAA-compliant, integrated telehealth solution that is easy to use and deploy has empowered my staff and patient community with the tools to ensure excellence of care is the hallmark of our practice.”

About Azalea Health:

Azalea Health (Azalea) is changing the way health IT platforms connect community-based healthcare providers and patients across the care continuum. Offering a 100% cloud-based, interoperable solution, Azalea delivers electronic health records, revenue cycle management, and telehealth services designed for rural, community and urban practices and hospitals, especially those focused on underserved populations. Quick to deploy and intuitive to use, Azalea solutions ensure better care coordination and communication, and the “one patient, one record” approach provides care teams the agility to achieve better outcomes. The Azalea platform also delivers tools and resources to help providers meet their Meaningful Use requirements, and informs their strategies to navigate accountable care and alternative payment models. For more information, visit http://www.azaleahealth.com.

Azalea PR Contact:

Lexi Herosian

lexi@scratchmm.com

Share article on social media or email: